Immunomedics Articles
Epratuzumab and Lupuzor have potential to offer improvements over Benlysta in reducing Lupus disease activity
4 April 2013
UCB and Immunomedics amend epratuzumab accord
29 December 2011
Showing 1-4 of 4 articles
- 1
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
